Table 3 Associations between the ESR1 and ESR2 genotype and prostatic cancer when stratified by smoking status
Smoking status | Genotype | Control N = 113 (%) | Case N = 127 (%) | OR (95 % CI) |
|---|---|---|---|---|
Never (N = 240) | rs2234693 ESR1 | |||
TT (Ref) | 31 (27.4 %) | 37 (29.1 %) | 1.00 | |
CT | 57 (50.4 %) | 63 (49.6 %) | 0.93 (0.51–1.68) | |
CC | 25 (22.1 %) | 27 (21.3 %) | 0.91 (0.44–1.87) | |
CT + CC | 82 (72.6 %) | 90 (70.9 %) | 0.92 (0.52–1.62) | |
rs1256049 ESR2 | ||||
GG (Ref) | 58 (51.3 %) | 68 (53.5 %) | 1.00 | |
AG | 45 (39.8 %) | 49 (38.6 %) | 0.93 (0.54–1.59) | |
AA | 10 (8.8 %) | 10 (7.9 %) | 0.85 (0.33–2.19) | |
AG + AA | 55 (48.7 %) | 59 (46.5 %) | 0.92 (0.55–1.52) | |
rs4986938 ESR2 | ||||
GG (Ref) | 78 (69.0 %) | 97 (76.4 %) | 1.00 | |
AG | 34 (30.1 %) | 28 (22.0 %) | 0.66 (0.37–1.19) | |
AA | 1 (0.9 %) | 2 (1.6 %) | 1.61 (0.14–18.07) | |
AG + AA | 35 (31.0 %) | 30 (23.6 %) | 0.69 (0.39–1.22) |
Smoking status | Genotype | Control N = 239 (%) | Case N = 225 (%) | OR (95 % CI) |
|---|---|---|---|---|
Ever | rs2234693 ESR1 | |||
(N = 464) | TT (Ref) | 49 (20.5 %) | 30 (13.3 %) | 1.00 |
CT | 118 (49.4 %) | 128 (56.9 %) | 1.17 (0.77–1.77) | |
CC | 72 (30.1 %) | 67 (29.8 %) | 0.66 (0.38–1.16) | |
CT + CC | 190 (79.5 %) | 195 (86.7 %) | 1.02 (0.68–1.51) | |
rs1256049 ESR2 | ||||
GG (Ref) | 109 (45.6 %) | 117 (52.0 %) | 1.00 | |
AG | 101 (42.3 %) | 93 (41.3 %) | 0.86 (0.58–1.26) | |
AA | 29 (12.1 %) | 15 (6.7 %) | 0.48 (0.25–0.95)* | |
AG + AA | 130 (54.4 %) | 108 (48.0 %) | 0.77 (0.54–1.12) | |
rs4986938 ESR2 | ||||
GG (Ref) | 176 (73.6) | 183 (81.3 %) | 1.00 | |
AG | 56 (23.4 %) | 39 (17.3 %) | 0.67 (0.42–1.06) | |
AA | 7 (2.9 %) | 3 (1.3 %) | 0.41 (0.11–1.62) | |
AG + AA | 63 (26.3 %) | 42 (18.6 %) | 0.64 (0.41–1.00)* | |